Opendata, web and dolomites

MycoSynVac SIGNED

Engineering of Mycoplasma pneumoniae as a broad-spectrum animal vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MycoSynVac project word cloud

Explore the words cloud of the MycoSynVac project. It provides you a very rough idea of what is the project "MycoSynVac" about.

genome    vaccine    free    serum    chassis    wall    industry    mycoplasma    species    pipeline    vaccination    cell    pigs    mycoplasmas    animal    poultry   

Project "MycoSynVac" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO CENTRE DE REGULACIO GENOMICA 

Organization address
address: CARRER DOCTOR AIGUADER 88
city: BARCELONA
postcode: 08003
website: www.crg.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 8˙056˙677 €
 EC max contribution 8˙056˙677 € (100%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
 Code Call H2020-LEIT-BIO-2014-1
 Funding Scheme /RIA
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) coordinator 2˙128˙507.00
2    Intervet International B.V. NL (BOXMEER) participant 1˙476˙250.00
3    ATG:BIOSYNTHETICS GMBH DE (Merzhausen) participant 897˙493.00
4    WAGENINGEN UNIVERSITY NL (WAGENINGEN) participant 860˙008.00
5    INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE FR (PARIS CEDEX 07) participant 850˙300.00
6    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 699˙977.00
7    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 591˙750.00
8    BIOFACTION KG AT (WIEN) participant 552˙392.00

Mappa

 Project objective

Mycoplasmas are the smallest cell wall less, free-living microorganisms. The lack of a cell wall makes them resistant to many of the common antibiotics. Every year, infections caused by Mycoplasmas in poultry, cows, and pigs, result in multimillion euros losses in USA and Europe. Currently, there are vaccines against M hyopneumoniae in pigs and M gallisepticum and M synoviae in poultry. However, there is no vaccination against many Mycoplasma species infecting pets, humans and farm animals (ie M bovis cow infection). Mycoplasma species in many cases are difficult to grown in axenic culture and those that grow need a complex media with animal serum. In large scale production of Mycoplasma species for vaccination aside from the high cost of animal serum, more important is the high irreproducibility in the production process and the possible contamination with animal viruses. All this together highlights what European industry needs:i) a defined cheap reproducible medium that is animal serum free and ii) an universal Mycoplasma chassis that could be used in a pipeline to vaccinate against Mycoplasma species, as well as any pathogen. M pneumoniae is an ideal starting point for designing such a vaccine chassis. It has a small genome (860 kb) and it is probably the organism with the most comprehensive systems biology data acquired so far. By genome comparison, metabolic modeling and rationally engineering its genome, we will create a vaccine chassis that will be introduced into an industrial pipeline. The process will be guided by the second world largest industry on animal vaccination (MSD), as well as a SME specialized on peptide display and screening. This will ensure the exploitation and commercialization of our work contributing to maintain Europe privileged position in this field. Our ultimate goal is to meet the needs of the livestock industry,taking care of ethical issues, foreseeable risks, and prepare effective dissemination and training material for the public.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYCOSYNVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYCOSYNVAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.)

BioRECO2VER (2018)

Biological routes for CO2 conversion into chemical building blocks

Read More  

CHIC (2018)

Chicory as a multipurpose crop for dietary fibre and medicinal terpenes

Read More  

BioCatPolymers (2018)

Sustainable and efficient bio-chemical catalytic cascade conversion of residual biomass to high quality biopolymers

Read More